Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.59 |
| ▸ | CDK7 | P50613 | 10/20 | 0.59 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292092 | 0.86 | CHEK1 (0.61) | CHEK1CDK7 | |
| SCHEMBL4297435 | 0.80 | CHEK1 (0.75) | CHEK1CDK7 | |
| SCHEMBL4289788 | 0.80 | CHEK1 (0.76) | CHEK1CDK7 | |
| SCHEMBL5066903 | 0.80 | CHEK1 (0.41) | CHEK1CDK7MPL | |
| SCHEMBL4287433 | 0.79 | CHEK1 (0.62) | CHEK1CDK7 | |
| SCHEMBL4287512 | 0.79 | CHEK1 (0.60) | CHEK1CDK7 | |
| SCHEMBL4289893 | 0.79 | CHEK1 (0.77) | CHEK1CDK7 | |
| SCHEMBL4291408 | 0.79 | CHEK1 (0.53) | CHEK1CDK7 | |
| SCHEMBL4291439 | 0.76 | CHEK1 (0.76) | CHEK1CDK7 | |
| SCHEMBL4296368 | 0.75 | CHEK1 (0.85) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | claimed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CDK7 39/4885MPL 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.